Pembrolizumab in Combination With CRT for LA-SCCHN

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: celltherapystagesquamoushead
  Phrases that lowered it: mgulndaypatientsopen label
• Sponsor's past termination rate: 40% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 22.9% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Drug's FAERS reports marked serious: 94.7% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 5 (raises risk) · Sponsor's track record
• Disease area, respiratory: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 27793 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Sponsor's past trials: 5 (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 4877 (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck NCT02819752 · started 2017 · scored riskier than 87% of active trials terminated
• Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin NCT02609503 · started 2016 · scored riskier than 96% of active trials completed
• Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) NCT03386357 · started 2018 · scored riskier than 78% of active trials terminated
• The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck NCT03057613 · started 2017 · scored riskier than 97% of active trials completed
• Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer NCT02718820 · started 2016 · scored riskier than 75% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.